Epstein-Barr virus infection in patients with MOGAD

Epstein-Barr virus (EBV) infection increases the risk of having multiple sclerosis (MS). Data on adults with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are lacking. To compare EBV serological status in MOGAD versus MS. We measured antibodies to Epstein-Barr nuclear antig...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis Jg. 31; H. 1; S. 117
Hauptverfasser: Maniscalco, Giorgia T, Dinoto, Alessandro, Foglia, Maria C, Di Battista, Maria E, Moreggia, Ornella, Di Giulio Cesare, Daniele, Williams, Michela, Rossi, Francesca W, Carta, Sara, Chiodega, Vanessa, Ferrari, Sergio, Viola, Assunta, de Paulis, Amato, Andreone, Vincenzo, Mariotto, Sara
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England 01.01.2025
Schlagworte:
Adult
Antibodies, Viral - blood
Antigens, Viral - blood
Antigens, Viral - immunology
Autoantibodies - blood
Capsid Proteins - immunology
Epstein-Barr Virus Infections - complications
Epstein-Barr Virus Infections - immunology
Epstein-Barr Virus Nuclear Antigens - blood
Epstein-Barr Virus Nuclear Antigens - immunology
Female
Herpesvirus 4, Human - immunology
Humans
Immunoglobulin G - blood
Male
Middle Aged
Multiple Sclerosis - blood
Multiple Sclerosis - immunology
Multiple Sclerosis - virology
Myelin-Oligodendrocyte Glycoprotein - immunology
Young Adult
EBNA-1
MOG
VCA
serology
EBV
Epstein-Barr virus
MOGAD
myelin oligodendrocyte glycoprotein
ISSN:1477-0970, 1477-0970
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Epstein-Barr virus (EBV) infection increases the risk of having multiple sclerosis (MS). Data on adults with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are lacking. To compare EBV serological status in MOGAD versus MS. We measured antibodies to Epstein-Barr nuclear antigen (EBNA-1) and viral capsid antigen (VCA) antigens in 129 patients (MS = 74, MOGAD = 55) by chemiluminescence immunoassays. VCA-IgG were detected in 97.3% of MS and 96.4% of MOGAD cases, while EBNA-1-IgG in 97.3% of MS and 80% of MOGAD ( = 0.001). EBNA-1 ( < 0.001) and VCA ( = 0.03) antibodies levels were higher in MS patients. EBV antibodies are higher in MS versus MOGAD, suggesting a possible different role of EBV in the pathogenesis of the two conditions.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1477-0970
1477-0970
DOI:10.1177/13524585241298065